Table 2.
Network meta-analysis of PFS (left) and percentage grade 3 or 4 AEs (right): P score ranking
| Efficacy | Safety | ||
|---|---|---|---|
| Treatment | P score | Treatment | P score |
| Cabozantinib | 0.9481 | Tivozanib | 0.9261 |
| Sunitinib (50 mg 4/2) | 0.7411 | Placebo | 0.9021 |
| Pazopanib | 0.6914 | Interferon-alfa | 0.7659 |
| Tivozanib | 0.5988 | Sunitinib (50 mg 2/1) | 0.4889 |
| Sunitinib (37.5 mg CDD) | 0.4714 | Pazopanib | 0.4254 |
| Sunitinib (50 mg 2/1) | 0.4528 | Sorafenib | 0.3844 |
| Sorafenib | 0.3651 | Cabozantinib | 0.2367 |
| Interferon-alfa | 0.1930 | Sunitinib (37.5 mg CDD) | 0.1926 |
| Placebo | 0.0384 | Sunitinib (50 mg 4/2) | 0.1778 |
CDD continuous daily dose, PFS progression-free survival